29 citations
,
December 2022 in “Journal of Nanobiotechnology” Stem cell vesicles reduced eczema symptoms in mice safely.
January 2022 in “The Egyptian Journal of Hospital Medicine” Higher IL-21 levels may help predict alopecia areata activity.
2 citations
,
June 2025 in “Journal of Investigative Dermatology”
Infliximab was effective in treating a scalp condition that did not respond to other treatments.
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
2 citations
,
July 2022 in “The Kaohsiung Journal of Medical Sciences” FTY720 helps transplanted fat survive better by reducing immune rejection and improving blood vessel growth.
February 2025 in “Journal of Clinical Investigation” RNase L hinders hair growth by altering immune signals.
2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
April 2025 in “The Journal of Dermatology” Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
11 citations
,
November 2015 in “Experimental Dermatology” The conclusion is that the IL-6/STAT3 activation affects p63 expression in healing wounds, which may help in hair follicle regeneration.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
November 2022 in “Journal of Investigative Dermatology” ILC1-like cells can cause alopecia areata by themselves.
April 2010 in “Cancer Research” Basal cell carcinomas may use IDO to protect themselves from the immune system.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
1 citations
,
January 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” Blocking IL-17 signaling can delay skin aging and improve skin and hair health.
March 2026 in “Journal of Translational Autoimmunity” Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.
April 2023 in “Journal of Investigative Dermatology” Type 1/17 inflammation in psoriasis increases skin cell growth due to a molecule that could be a new treatment target.
IL-1 and IL-7 help activate cells that boost hair follicle stem cell growth, aiding wound healing.
September 2016 in “Journal of Dermatological Science” Plasmacytoid dendritic cells, which overproduce IFN-α, may play a crucial role in starting alopecia areata, an autoimmune disease causing hair loss.
15 citations
,
October 2022 in “Allergy” Dupilumab treatment reduces Th2-related markers and helps hair growth in alopecia areata, showing Th2's role in the condition.
2 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.
1 citations
,
March 2026 in “American Journal of Clinical Dermatology”
Belimumab effectively controls SLE disease activity and reduces steroid use.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Laminin-511 is involved in psoriasis development and can be regulated by cannabinoid receptor type 1.
August 2025 in “JEADV Clinical Practice” Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.
6 citations
,
May 2023 in “Dermatology Research and Practice” IL-15 and TNF-α levels are higher in alopecia areata patients, especially in alopecia totalis.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
A new compound from Royoporus badius activates immune cells and induces inflammatory responses.
1 citations
,
October 2013 in “The American Journal of Gastroenterology” Infliximab can trigger lupus-like symptoms in Crohn's disease patients.